• High Tide issued preliminary Q3 guidance for revenue of C$ 195-200 million, implying 9%-12% sequential growth.
• Revenue outlook implies 30%-34% year-over-year growth, above FactSet analyst consensus of C$ 183.4 million.
• Gross profit forecast at C$ 51-53.5 million, implying 5%-11% sequential growth, 27%-33% year-over-year growth.
• Adjusted EBITDA seen at C$ 15.2-16.5 million, implying 9%-19% sequential growth, 43%-55% year-over-year growth.
• Remexian Pharma GmbH distributed over 10 tonnes of medical cannabis flower in the quarter, up 33% sequentially, 60% year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. High Tide Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040600PR_NEWS_USPR_____CA18528) on August 04, 2026, and is solely responsible for the information contained therein.